Trial Profile

A first-in-human single-ascending and multiple-ascending dose study of SF001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SF 001 (Primary)
Indications Invasive fungal infections
Focus Adverse reactions; First in man

Most Recent Events

21 Jun 2024 New trial record
18 Jun 2024 According to Elion Therapeutics media release, single-ascending dose study has been completed and is now being evaluated in a multiple-ascending dose study.
18 Jun 2024 According to Elion Therapeutics media release, company announced today it has closed a $81 million Series B funding to support the advancement of SF001

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com